NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









U-CyTech biosciences

U-CyTech biosciences

Private
UtrechtHealthcare & Life Scienceshttps://www.ucytech.com/

Last Round

Early Funding

Sep 13, 2024

Total Funding Raised

$9.97M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

U-CyTech biosciences is a biotechnology company that develops, produces, and sells innovative cytokine ELISA, ELISPOT, and FluoroSpot assays for research use.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

ELISpotFluoroSpotELISAimmunoassaycytokine detectionmonoclonal antibodiesimmune monitoringrecombinant proteinsmultiplex assaylab reagentsbiotech research toolscustom assay developmentsingle-cell analysiswet lab

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

U-CyTech biosciences Comparables

Compare U-CyTech biosciences with similar companies based on industry and business-model similarity.

U-CyTech biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Mabtech AB
84%
VION Biosciences
83%
Neomend
79%

U-CyTech biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingSep 13, 2024

Key People

Founding team and executive leadership

Nicole van Besouw

CEO

Executive Team

Gwen van den Brand

Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Monthly visitors grew 1610% MoM, reaching 1.3K.

  • Oct 15, 2023

    Grew 175% QoQ from 4 to 11 employees.

U-CyTech biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

U-CyTech biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about U-CyTech biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersUtrecht
Employee Range7
Year Founded1999
Last FundingSep 13, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.